Review of Flunarizine in Epilepsy

  • C. D. Binnie
  • F. de Beukelaar
  • J. Overweg
Conference paper


A feature of epileptogenesis is burst firing of individual neurons. The burst comprises a slow paroxysmal depolarizing ion shift (PDS) upon which is superimposed a train of action potentials [6, 36]. Bursting depends largely on influx of Ca2+, although other ionic currents are also involved [37, 56].


Calcium Antagonist Concentration Of30 Tonic Seizure Calcium Entry Blocker Paroxysmal Depolarization Shift 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ashton D (1983) Bicuculline seizure thresholds, actions of diazepam, pentobarbital and etomidate isomers alone and in combination with Ro 15-1788, Picrotoxin and (±) DMBB. Eur J Pharmacol 94:319–325PubMedCrossRefGoogle Scholar
  2. 2.
    Ashton D, Wauquier A (1979a) Effects of some anti-epileptic, neuroleptic and gabaminergic drugs on convulsions induced by d,l-allylglycine. Pharmacol Biochem Behav 11:221–226CrossRefGoogle Scholar
  3. 3.
    Ashton D, Wauquier A (1979b) Behavioural analysis of the effects of 15 anticonvulsants in amygdaloid kindled rats. Psychopharmacology 65:7–13CrossRefGoogle Scholar
  4. 4.
    Ashton D, Wauquier A (1985) Modulations of a gaba-ergic inhibitory circuit in the in vitro hippocampus by etomidate isomers. Anaesth Analg 64:975–980CrossRefGoogle Scholar
  5. 5.
    Ashton D, Marannes R, Pauwels PJ, Van Belle H, Reid K, Wauquier A (1986) Possible mechanisms of flunarizine’s anticonvulsant activity. Health Science Review: International Workshop on Flunarizine in Epilepsy, Beerse, 24 May 1985, p 45–59Google Scholar
  6. 6.
    Ayala GF, Dichter M, Gumnit RZ, Matsumoto H, Spencer WA (1973) Genesis of epileptic interictal spikes: new knowledge of cortical feedback systems suggest a neurophysiological explanation of brief paroxysms. Brain Res 211:227–234Google Scholar
  7. 7.
    Bergamasco B, Cantello R, Riccio A (1987) Utilita della flunarizina come coordiuvante nel trattamento dell’epilessia (confronto in doppio cieco con un placebo in disegno cross over) (unpublished report)Google Scholar
  8. 8.
    Bidard JN, Vijverberg HPM, Frelin C, Chungue E, Legrand A-M, Bagnis R, Ladunski M (1984) Cignatoxin is a novel type of Na+ channel toxin. J Biol Chem 259:8253–8357Google Scholar
  9. 9.
    Bingmann D, Speckmann EJ (1984) Paroxysmal depolarization shifts in neurons of hippocampal slices: depression by calcium antagonists. Pflugers Arch S402, R29Google Scholar
  10. 10.
    Binnie CD, de Beukelaar F, Meijer JWA, Meinardi H, Overweg J, Wauquier A, van Wieringen A (1985) Open dose-ranging trial of flunarizine as add-on therapy in epilepsy. Epilepsia 26:424–428PubMedCrossRefGoogle Scholar
  11. 11.
    Caspers H, Speckmann EJ, Lehmkühler A (1980) Electrogenesis of cortical DC potentials. In: Kornhuber HH, Deecke L (eds) Motivation motor and sensory processes of the brain: electrical potentials, behaviour and clinical use. Prog Brain Res 54:3–15Google Scholar
  12. 12.
    Cavazzuti GB, Galli V, Benatti A (1986) The use of flunarizine in pediatric epilepsy. Funct Neurol 1:551–554PubMedGoogle Scholar
  13. 13.
    Curatolo P, Bruni O, Brindesi I, Pruna D, Cusmai R (1986) La flunarizina nelle epilessie formaco-resistenti deH’infanzia e dell’adolescenza. Riv Neurol 56:25–38PubMedGoogle Scholar
  14. 14.
    Debandt R, De Smedt R, Jorens H, Leysen M, Rodrigus E, Van Eycken L (1985) Flunarizine as “add-on” therapy in institutionalized patients with refractory epilepsy. Effect on seizure incidence and behaviour. Janssen Research Product Information Service: CRR R 14950/65Google Scholar
  15. 15.
    Declerck AC, Wauquier A (1978) Double-blind study on the effectiveness on flunarizine in therapy-resistant epilepsy in mentally retarded children (abstr). 10th Epilepsy International Symposium, p 169Google Scholar
  16. 16.
    Declerck AC, Wauquier A (1983) Flunarizine, a double-blind study in therapy resistant mentally retarded epileptic children. Suppl Boll Chim Farm 122:9CL–16CLGoogle Scholar
  17. 17.
    Declerck AC, Oei LT, Wauquier A (1986) Flunarizine in mentally retarded children with therapy-resistant epilepsy. Health Science Review: International Workshop of Flunarizine in Epilepsy, Beerse, 24 May 1985, p 68Google Scholar
  18. 18.
    De Domenico P, Gallitto G, Musolino R, Di Perri R (1987) Saggio dell “Utilita” condiuvante della flunarizina in epilettia gravi (unpublished report)Google Scholar
  19. 19.
    De Sarro GB, Nistico G, Meldrum B (1986) Anticonvulsant properties of flunarizine on reflex and generalised models of epilepsy. Neuropharmacology 25:695–701PubMedCrossRefGoogle Scholar
  20. 20.
    De Sarro GB, Meldrum BS, Nistico G (1988) Anticonvulsant effects of some calcium entry blockers in DBA/2 mice. Br J Pharmacol 93:247–256PubMedGoogle Scholar
  21. 21.
    Desmedt LKC, Niemegeers CJE, Janssen PAJ (1975) Anticonvulsant properties of cinnarizine and flunarizine in rats and mice. Arzneimittelforschung 25:1408–1413PubMedGoogle Scholar
  22. 22.
    Fröscher W, Bülau P, Burr W et al. (1988) Double-blind, placebo-controlled trial in flunarizine in therapy-resistant persons with epilepsy. Clin Neuropharmacol (in press)Google Scholar
  23. 23.
    Giroud M, Nivelon JL, Dumas R (1987) Antiepileptic activity of flunarizine in 10 therapy-resistant children with epilepsy. Presse Med 16:913PubMedGoogle Scholar
  24. 24.
    Heinemann U, Lux HA, Gutnick MJ (1977) Extracellular free calcium and potassium during paroxysmal activity in the cerebral cortex of the rat. Exp Brain Res 27:237–243PubMedCrossRefGoogle Scholar
  25. 25.
    Heykants J, De Cree J, Hörig C (1979) Steady-state plasma levels of flunarizine in chronically treated patients. Arzneimittelforschung 29:1168–1171PubMedGoogle Scholar
  26. 26.
    Keene D, Whiting S, Humphreys P, Findlay HP, Cumming B (1987) Flunarizine, an add-on drug in the treatment of refractory childhood epilepsy. XXIInd Canadian congress of neurological sciences. Vancouver, June 1987Google Scholar
  27. 27.
    Konishi T, Murakami M, Yamatani M, Koda O, Okada T, Seto H, Nitani T (1987) Efficiency of flunarizine (a calcium entry blocker in therapy resistant epileptic children with partial epilepsy). The 20th Congress of the Japanese Society of Epilepsy: Abstract Book, p 131Google Scholar
  28. 28.
    Mancia D (1987) La flunarizina come coordiuvante della terapia di base nel trattamento dell’epilessia (Studio clinico controllato) (unpublished report)Google Scholar
  29. 29.
    Meldrum BS (1979) Convulsant drugs, anticonvulsants and GABA-mediated neuronal inhibition. In: Krogsgaard-Larsen P, Scheel-Kruger J, Kofod H (eds) Gaba-neurotransmitters. Munksgaard, Copenhagen, pp 390–405Google Scholar
  30. 30.
    Meldrum BS (1983) Convulsants and anticonvulsant drug mechanisms. In: Baldy-Moulinier M, Ingvar DH, Meldrum BS (eds) Current problems in epilepsy. Libbey, London, pp 324–336Google Scholar
  31. 31.
    Moglia A, Bergamasco B, Di Perri R, Mancia D (1986) Flunarizine as add-on therapy in epilepsy, cross over study versus placebo. Furet Neurol 1:547–550Google Scholar
  32. 32.
    Olsen RW (1982) Drug interactions at the GABA-receptor ionophore complex. Annu Rev Pharmacol Toxicol 22:245–277PubMedCrossRefGoogle Scholar
  33. 33.
    Overweg J (1987) Safety evaluation of flunarizine after long-term “add-on” administration in epileptic patients. Janssen Research Product Information Service, Clinical Research Report, R14 950/71Google Scholar
  34. 34.
    Overweg J, Binnie CD, Meijer JWA, Meinardi H, Nuijten STM, Schmaltz S, Wauquier A (1984) Double-blind placebo-controlled trial of flunarizine as add-on therapy in epilepsy. Epilepsia 25:217–222PubMedCrossRefGoogle Scholar
  35. 35.
    Pothmann R, Braumann G, Kröger T (1986) Calciumeintrittsblockade als Zusatz-Behandlung bei therapieresistenten kindlichen Epilepsien. Deutsche Sektion der Internationalen Liga gegen Epilepsie: 26. Jahrestagung, Münster, Abstract, p 56Google Scholar
  36. 36.
    Prince DA (1978) Neurophysiology of epilepsy. Annu Rev Neurosci 1:395–415PubMedCrossRefGoogle Scholar
  37. 37.
    Prince DA (1982) Epileptogenesis in hippocampal and neocortical neurones. In: Klee MR, Lux HD, Speckman EJ (eds) Physiology and pharmacology of epileptogenic phenomena. Raven, New York, pp 151–161Google Scholar
  38. 38.
    Sorel L (1987) La flunarizine dans l’epilepsie: evaluation d’un traitement “additif” de quatre nous chez des patients resistant au traitement antiépileptique existant. Acta Neurol Belg 87:140–147PubMedGoogle Scholar
  39. 39.
    Starreveld E et al. Flunarizine in epilepsy (in preparation)Google Scholar
  40. 40.
    Study RE, Barker JL (1981) Diazepam and (—) pentobarbital: fluctuation analysis reveals different mechanisms for the potentiation of G AB A responses in cultured central neurones. Proc Natl Acad Sci USA 78:7180–7184PubMedCrossRefGoogle Scholar
  41. 41.
    Takahashi T (1988) An open trial of flunarizine hydrochloride as add-on treatment in therapy-resistant epileptics. Clin Psychiatry (in press)Google Scholar
  42. 42.
    Tata MR, Guizzaro A, Giudici S, Parisi A, Bravaccio F (1987) Flunarizine in pharmacoresistant epilepsies: preliminary experiences in 30 cases. International Symposium on Calcium Antagonists, Pharmacology and Clinical Research, New York City, 10–13 February 1987, p 113Google Scholar
  43. 43.
    Touquet G, Van Cappel F (1985) Flunarizine as adjuvants in therapy resistant epilepsy, a double-blind placebo-controlled trial. Janssen Research Product Information Service, Clinical Research Report No. 14950/64Google Scholar
  44. 44.
    Treiman DM, De Giorgio CM, Cornish JW, Cereghino JJ (1986) Efficacy and toxicity of flunarizine in partial onset seizures at concentrations of 30, 60,120 ng/ml. Epilepsia 27:649–650CrossRefGoogle Scholar
  45. 45.
    Treiman DM, Tsay J-Y, Whitley LP, Seaman CA, Kupferberg HJ, Pledger GW, Cereghino JJ (1987) Final report of flunarizine open tolerability study. Epilepsy Res NINCDS, BethesdaGoogle Scholar
  46. 46.
    Umezawa Y, Amano K, Kawamurah H et al. (1987) Add-on therapy of flunarizine in therapy-resistant epilepsy. The 20th Congress of the Japanese Society of Epilepsy. Abstract Book p 92Google Scholar
  47. 47.
    Van Bever W (1974) Acute oral toxicity (LD50) of flunarizine dihydrochloride in mice, rats and guinea pigs. Janssen Pharmaceutica, Preclinical Research Report R14950/1 December 1974Google Scholar
  48. 48.
    Van Wieringen A, Ashton D, De Beukelaar F, Binnie CD, Overweg J, Wauquier A (1986) Flunarizine in the treatment of epilepsy. In: Schalse H, Walden J (eds) Epilepsy and calcium. Urban & Schwartzenberg, Munich, pp 387–399Google Scholar
  49. 49.
    Walden J, Speckmann EJ, Witte OW (1984) Effects of the calcium antagonist verapamil on spontaneous and evoked bioelectric activity on the cerebral cortex. Pflugers Arch 402:R36Google Scholar
  50. 50.
    Walden J, Speckmann EJ, Witte OW (1985) Suppression of focal epileptiform discharges by intracerebroventricular perfusion of a calcium antagonist. Electroencephalogr Clin Neurophysiol 61:299–309PubMedCrossRefGoogle Scholar
  51. 51.
    Wauquier A, Ashton D, Melis W (1979) Behavioural analysis of amygdaloid kindling in Beagle dogs and the effects of clonazepam, diazepam, phénobarbital, diphenylhydantoin and flunarizine on seizure manifestation. Exp Neurol 64:579–586PubMedCrossRefGoogle Scholar
  52. 52.
    Wauquier A, Ashton D, Clincke G, Fransen J, Gillardin JM, Janssen PAJ (1986) Anticonvulsant profile of flunarizine. Drug Dev Res 7:49–60CrossRefGoogle Scholar
  53. 53.
    Willow M, Catterall WA (1982) Inhibition of binding of [3H] batrachotoxin in A-20-α-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol 22:627–635PubMedGoogle Scholar
  54. 54.
    Witte OW, Walden J, Speckmann EJ, Elger CE (1983) Reduction of penicillin-induced paroxysmal depolarization shifts in neurons of rat cerebral cortex by intracellular injection of calcium channel blocker. Neurosci Lett Suppl 14:S405Google Scholar
  55. 55.
    Witte OW, Speckmann EJ, Walden J (1984) Contribution of calcium and calcium-dependent membrane currents to epileptic discharges in neocortical neurons of the rat. Cell Calcium 5:311CrossRefGoogle Scholar
  56. 56.
    Wong RKS, Prince DA, Basbaum AI (1979) Dendritic mechanisms underlying penicillin induced epileptiform activity. Science 204:1228–1231PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • C. D. Binnie
    • 1
  • F. de Beukelaar
    • 2
  • J. Overweg
    • 3
  1. 1.The Maudsley HospitalLondonUK
  2. 2.Janssen Pharmaceutica B.V.B-BeerseBelgium
  3. 3.Instituut voor EpilepsiebestrijdingHeemstedeThe Netherlands

Personalised recommendations